Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
DGXQuest Diagnostics, Inc. -0.33%153.014.7%$189.20m
LHLaboratory Corp. of America Holdings -0.19%296.182.4%$171.78m
IQVIQVIA Holdings, Inc. -0.16%261.860.0%$147.90m
AMEHApollo Medical Holdings, Inc. -0.78%95.620.0%$94.15m
NOTVInotiv, Inc. 1.81%34.320.0%$7.39m
PLXProtalix Biotherapeutics, Inc. -4.38%1.3118.5%$1.70m
NRCNational Research Corp. -1.35%45.160.0%$1.10m
QIPTQuipt Home Medical Corp. -1.17%5.900.0%$0.37m
PMDPsychemedics Corp. 3.32%8.400.7%$0.31m

Company Profile

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.